Alkem Laboratories Ltd. is an Indian multinational pharmaceutical company. Samprada Singh, a pharmaceutical industry veteran, launched the company in 1973. Alkem Laboratories has evolved into a global pharmaceutical corporation with a significant presence in over 50 countries since its beginnings.
On August 8, 1973, the Company was incorporated as a private limited company ‘Alkem Laboratories Private Limited’ in Patna under the Companies Act, 1956, and on October 26, 1988, it became a presumed public limited company under section 43A(2) of the Companies Act, 1956.
The company, based in Mumbai, manufactures and sells pharmaceutical generics, formulations, and nutraceuticals in India and around the world.
Mr. Prabhat Agrawal was the CEO of Alkem Laboratories from October 2014 to March 2018.
Mr. Sandeep Singh, Managing Director at Alkem laboratories ltd and Co-founder of Bluetribe Foods, currently manages the company. Sandeep Singh has been instrumental in Alkem Laboratories’ growth and expansion, and is credited with pushing the company’s focus on innovation and quality. Under his direction, the company has expanded its global footprint and grown to become one of India’s premier pharmaceutical corporations.
The company manufactures and sells branded generics, generic pharmaceuticals, active pharmaceutical ingredients (APIs), and nutraceuticals in India and internationally. Alkem is the sixth largest pharmaceutical firm in India in terms of domestic sales, with a portfolio of over 700 brands.
In addition, the company has a presence in over 50 overseas regions, with the United States being its primary focus area. Offshore sales account for 33% of our revenue.
Alkem Laboratories Ltd is a Great Place to Work-accredited company. By succeeding on the five aspects of a High-Trust, High-Performance CultureTM – Credibility, Respect, Fairness, Pride, and Camaraderie – Alkem Laboratories Ltd has established a great place to work for all of their employees.
Here are some significant turning points in Alkem Laboratories’ history:
- Alkem Laboratories built its first manufacturing unit in Taloja, Maharashtra, India, in 1978.
- In 1992, a second production facility in Mandva, Gujarat, was created, which was turned into an API factory in 2005.
- Taloja’s first research and development facility was created in 2003.
- Taxim became India’s first anti-infective medicine to sell more than Rs. 1,000 million in the domestic market in 2006.
- In 2007, the first ANDA for the medication Amoldipine was filed in the United States.
- In 2009, the business received the first ANDA in the United States for the medicine Amoldipine and purchased Pharmacor Pty. Ltd., an Australian generic pharmaceutical company.
- Acquired Ascend Laboratories, a pharmaceutical firm based in the United States, in 2010.
- Acquired Enzene, an Indian business involved in the development of biosimilars, in 2011.
- Acquired an API production facility in the United States in 2012.
- Acquired the ‘Clindac-A’ brand in India from Galderma S.A. in 2014.
- Acquired a formulation production plant in the United States in 2015 and successfully launched its “IPO.”
- In 2017, Tiger Balm formed a marketing collaboration with Haw Par to exclusively advertise, sell, and distribute the Tiger Balm product line in India.
- Annual sales in the US market exceeded $200 million in 2018.
- In 2019, we passed the $1 billion revenue mark.
- In 2020, a new formulation manufacturing facility in Indore and a biologic/biosimilar manufacturing facility in Pune will be operational.
Enzene Biosciences introduced its first product in India in 2021, and the firm forayed into the respiratory segment with the introduction of the Pulmocare division.
Finally, Alkem Laboratories Ltd’s success may be due to its dedication to quality, innovation, and client happiness. The company’s excellent R&D team, cutting-edge manufacturing facilities, and extensive distribution network have helped it to grow and extend its business both locally and abroad.
Disclaimer – If you come across any concerns regarding the content, kindly reach us at editorial@ceovine.com, and we will address them within the next 48 hours.
